{"id":"NCT00401531","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants","officialTitle":"Immunogenicity Study of a DTaP IPV Hep B PRP T Combined Vaccine in Comparison to Infanrix Hexa™, Both Concomitantly Administered With Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2007-11","completion":"2008-08","firstPosted":"2006-11-20","resultsPosted":"2014-04-01","lastUpdate":"2014-04-01"},"enrollment":412,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B","Polio","Diphtheria","Pertussis","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines","otherNames":["Prevnar®"]},{"type":"BIOLOGICAL","name":"DTaP-HB-IPV and Pneumococcal polysaccharide vaccines","otherNames":["Infanrix™-Hexa","Prevnar®"]}],"arms":[{"label":"Group 1: DTaP IPV Hep B PRP T + Prevnar™","type":"EXPERIMENTAL"},{"label":"Group 2: Infanrix hexa™ + Prevnar™","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection sites) with Prevnar, according to the 2-4-6 month immunization schedule, following one dose of HB vaccine at birth.\n\nPrimary Objective:\n\nTo demonstrate that the hexavalent DTaP-IPV-HB-PRP\\~T combined vaccine induces an immune response that is at least as good as the response following Infanrix™-Hexa in terms of seroprotection rates to HB and PRP, one month after a 3 dose primary series (2, 4, and 6 months), when co-administered with Prevnar®\n\nSecondary Objectives:\n\nImmunogenicity:\n\nTo describe in each group the immunogenicity parameters to each vaccine component (for DTaP-IPV-HB-PRP\\~T and Infanrix™-Hexa) one month after the third dose of the primary series.\n\nSafety:\n\nTo describe the overall safety after each injection.","primaryOutcome":{"measure":"Number of Participants Achieving Seroprotection Against Hepatitis B and Haemophilus Influenzae Type b Post-vaccination With Either DTaP-IPV-Hep B-PRP~T + Prevnar™ or Infanrix Hexa™ + Prevnar™","timeFrame":"Day 150 post-dose 1","effectByArm":[{"arm":"DTaP-IPV-Hep B-PRP-T + Prevnar™","deltaMin":187,"sd":null},{"arm":"Infanrix Hexa™ + Prevnar™","deltaMin":189,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":2,"countries":["Thailand"]},"refs":{"pmids":["21334243"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":206},"commonTop":["Injection Site Pain","Irritability","Crying","Somnolence","Injection Erythema"]}}